Screening Test For Cells That Activate Immune System Developed
News Sep 07, 2005
UT Southwestern Medical Center researchers have announced a cell-based screening method that identifies which compounds activate immune-response cells that hold promise for future cancer-fighting vaccines.
Researchers claims that, the screening technique can scan thousands and even millions of compounds to identify those that activate dendritic cells, which are on constant recon patrol throughout the body to scout out cancerous or infected cells and alert the immune system.
"Our assay is unique from other conventional ones in its sensitivity and cost- and time-efficiency," said Dr. Akira Takashima, professor of dermatology and vice chairman for research and head of the project.
"We basically engineered DCs to express a fluorescent signal only when sensing activation signals so that you can identify immuno-stimulatory agents very easily," said Dr. Takashima. Immuno-stimulatory agents launch the immune system.
The research appears on Blood magazine's online Web site and will appear in a future issue.
"We have optimized the high-throughput screening capability - an experienced scientist can now test one thousand chemicals a day almost single-handedly," added Dr. Mizumoto. Previously, scientists would have to test each compound individually, a time-consuming process.
Their research already has led to the discovery of several compounds that turn on dendritic cells, which are found throughout the body from skin to blood.
They continuously scan the body at the cellular level looking for antigens - foreign cells and materials invading the body - and for molecular signatures of tissue damage or infection.
"Their primary job is to present antigens to the immune system so that you develop protective immunity for infection and cancer," said Dr. Takashima.
The DC biosensor system should help pharmaceutical and biotech companies sift through large numbers of chemicals for ones that tell the dendritic cells to launch the immune response.
According to researchers, it may also prove useful in identifying biothreat agents because it detects infectious pathogens with high sensitivity.
Dr. Takashima said he hopes to garner additional funding to discover potent immuno-stimulatory drugs by screening high-quality libraries of compounds.
Avacta Group plc announces successful outcome of “Gene Delivery” collaboration with FIT BiotechNews
Sustained production of Affimer drugs by muscle tissue in vivo could lead to major patient and commercial benefits.READ MORE
XenoGesis and BioAscent Forge Alliance to Offer Enhanced Integrated Drug Discovery ServicesNews
XenoGesis and BioAscent Discovery Limited have announced a collaboration to offer an enhanced range of integrated drug discovery services, including medicinal chemistry, biology and DMPK.READ MORE
BioAscent Establishes Integrated Drug Discovery Services OfferingNews
Dr Phil Jones to join as new CSO to lead company’s extended capabilities in medicinal chemistry and in vitro biosciences.READ MORE